Biotech: Page 23
-
Getty Images
Evommune raises $115M to accelerate immune drug tests
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” regarding an IPO, its CEO said.
By Gwendolyn Wu • Oct. 31, 2024 -
Permission granted by Axonis Therapeutics
Investors put $115M into Axonis amid revived interest in brain drugs
The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision therapies for neurological diseases, one investor told BioPharma Dive.
By Jacob Bell • Oct. 30, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Permission granted by Sage Therapeutics
Biogen, Sage admit a defeat in major depression
The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.
By Kristin Jensen • Oct. 30, 2024 -
Jacob Bell/BioPharma Dive
Biogen optimistic as new products gain traction
Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business, according to one analyst.
By Jacob Bell • Oct. 30, 2024 -
Permission granted by Archon Biosciences
A new biotech, built around protein design, springs from David Baker’s lab
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital.
By Gwendolyn Wu • Oct. 30, 2024 -
Getty Images
Paragon spinout joins hunt for new type of cancer immunotherapy
Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ivonescimab, which recently beat Merck’s Keytruda in a Phase 3 trial.
By Ben Fidler • Oct. 29, 2024 -
Getty Images
Biogen refreshes its C-suite; Novartis writes down MorphoSys assets
Daniel Quirk, an immunology and neuroscience executive at Bristol Myers Squibb, will be Biogen’s next chief medical officer. Meanwhile, Robin Kramer will replace retiring CFO Michael McDonnell.
By BioPharma Dive staff • Oct. 29, 2024 -
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal
Novartis follows cross-town rival Roche in partnering with Monte Rosa Therapeutics on so-called molecular glue degraders that can target “undruggable” proteins.
By Ned Pagliarulo • Oct. 28, 2024 -
Kyodo/Newscom
After Pfizer deal, former Seagen CEO returns to lead oncology startup
David Epstein has joined Ottimo Pharma, which is developing an antibody drug that board member and longtime Roche dealmaker James Sabry claims could “change the face of cancer immunotherapy.”
By Ben Fidler • Oct. 28, 2024 -
Permission granted by Kivu Biosciences
With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs
The startup claims its proprietary linker molecules can yield ADCs that are more precise and potent than existing options.
By Gwendolyn Wu • Oct. 27, 2024 -
Getty Images
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, Roche and Dyno expanded their alliance to create better viral vectors for use in gene therapy.
By BioPharma Dive staff • Oct. 25, 2024 -
Michael M. Santiago via Getty Images
GPCR drugmaker Septerna amasses $288M in IPO
Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a treatment for hypoparathyroidism now in Phase 1 testing.
By Gwendolyn Wu • Oct. 24, 2024 -
Permission granted by BIO
Q&A // Emerging biotechJ&J’s Asish Xavier on biotech’s rebound in a volatile era
Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in the newer crop of gene and cell therapy companies.
By Gwendolyn Wu • Oct. 24, 2024 -
Getty Images
Alto hits new low as depression drug flunks key test
While analysts still see value in Alto’s approach to brain drugmaking, investors may have lost some faith, as the biotech’s shares were down by two-thirds Wednesday morning.
By Jacob Bell • Oct. 23, 2024 -
Getty Images
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market for its Fabry gene therapy.
By BioPharma Dive staff • Oct. 23, 2024 -
Permission granted by Editas Medicine
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its treatment reni-cel.
By Ned Pagliarulo • Oct. 22, 2024 -
Getty Images
Otsuka’s startup bet pays off with kidney disease drug results
A medicine the pharma acquired in a 2018 buyout of Visterra succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
By Ben Fidler • Oct. 22, 2024 -
Getty Images
Deep Dive // State of PlayRNA editing: emerging from CRISPR’s shadow
Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
By Ben Fidler , Gwendolyn Wu • Oct. 22, 2024 -
Permission granted by PureTech Health
Q&A // Emerging biotechPureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.
Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a "huge value disconnect" its leaders are trying to bridge.
By Jacob Bell • Oct. 21, 2024 -
Getty Images
Brain drug developer Seaport raises another $225M
Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.
By Jacob Bell • Oct. 21, 2024 -
Getty Images
Sponsored by AltasciencesPharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
Oct. 21, 2024 -
Getty Images
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.
By BioPharma Dive staff • Oct. 18, 2024 -
Getty Images
Sage to cut one-third of workforce, streamline drug pipeline
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
By Delilah Alvarado • Oct. 17, 2024 -
Getty Images
Forbion follows string of startup exits with $2.2B fundraise
The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.
By Delilah Alvarado • Oct. 15, 2024 -
Getty Images
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.
By BioPharma Dive staff • Oct. 15, 2024
Previous
